Addax Biosciences is pleased to announce its selection as a finalist for the "Premio PMI Innovativa Piemonte 2024" a prestigious accolade promoted by InnovUp,...
MEDICA 2024 has officially started in Düsseldorf! Addax Biosciences is thrilled to be part of one of the world’s most prestigious events for the medical indu...
Addax Biosciences is proud to be a key partner in 𝗦𝗖𝗥𝗔𝗧𝗖𝗛 Project, a pioneering initiative within the Eurostars 3 funding program, managed...
Following our participation in the European Congress of Pathology (ECP) 2024, which concluded last month, Addax is preparing to participate in a series of major...
The US Environmental Protection Agency (EPA) has made significant strides in assessing the health risks associated with formaldehyde, culminating in the recent...
A recent study has highlighted the occupational hazards associated with formaldehyde exposure, significantly impacting not only pathologists and laboratory tec...
We are pleased to have participated in the 36th European Congress of Pathology (ECP 2024), the largest event in the pathology field in Europe, held from Septemb...
Starting July 12, 2024 the healthcare sector must comply with the new, stricter occupational exposure limits for formaldehyde, marking the end of the 5-year tra...
Addax Biosciences is excited to share that our acid-free glyoxal formulation has been used in a recent study, demonstrating superior performance in preserving n...
We are pleased to share another significant step in the entrepreneurial development of Addax Biosciences: Fintech Partners, investment sub-holding controlled by...